{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:56:11Z","timestamp":1783641371573,"version":"3.55.0"},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2021,4,30]]},"DOI":"10.18632\/aging.202902","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T15:42:38Z","timestamp":1619106158000},"page":"10853-10865","source":"Crossref","is-referenced-by-count":9,"title":["Does taking an angiotensin inhibitor increase the risk for COVID-19? \u2013 a systematic review and meta-analysis"],"prefix":"10.18632","volume":"13","author":[{"given":"Zheng","family":"Ma","sequence":"first","affiliation":[{"name":"Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Chaoyang 100020, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Fengtai 100054, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Fengtai 100070, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Yu","sequence":"additional","affiliation":[{"name":"Yuetan Community Health Service Center, Fuxing Hospital, Capital Medical University, Xicheng 100045, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Ran","family":"Wu","sequence":"additional","affiliation":[{"name":"Monash Medical Centre, Clayton, VIC 3168, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Chaoyang 100020, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Chaoyang 100020, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Feng","family":"Liang","sequence":"additional","affiliation":[{"name":"Heart Center, Fuxing Hospital, Capital Medical University, Xicheng 100038, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Chun","family":"Yang","sequence":"additional","affiliation":[{"name":"Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Chaoyang 100020, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges.","volume":"5","author":"Hsueh","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12098-020-03263-6","article-title":"A Review of Coronavirus Disease-2019 (COVID-19).","volume":"8","author":"Singhal","year":"2020","journal-title":"Indian J Pediatr"},{"key":"3","doi-asserted-by":"publisher","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.","volume":"10","author":"Byrareddy","year":"2020","journal-title":"J Autoimmun"},{"key":"4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.","volume":"32","author":"Cutrell","year":"2020","journal-title":"JAMA"},{"key":"5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","volume":"18","author":"P\u00f6hlmann","year":"2020","journal-title":"Cell"},{"key":"6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/Angiotensin-(1-7)\/MAS Axis of the Renin-Angiotensin System: focus on Angiotensin-(1-7).","volume":"9","author":"Campagnole-Santos","year":"2018","journal-title":"Physiol Rev"},{"key":"7","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.","volume":"11","author":"Gallagher","year":"2005","journal-title":"Circulation"},{"key":"8","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/cvr\/cvaa097","article-title":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.","volume":"11","author":"Burnier","year":"2020","journal-title":"Cardiovasc Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"taaa041","DOI":"10.1093\/jtm\/taaa041","article-title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.","volume":"2","author":"Diaz","year":"2020","journal-title":"J Travel Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"e016509","DOI":"10.1161\/JAHA.120.016509","article-title":"Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers Have a Biphasic Effect?","volume":"9","author":"Gr\u00e4ni","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"11","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1093\/cid\/ciaa634","article-title":"Therapy With Agents Acting on the Renin-Angiotensin System and Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.","volume":"7","author":"Costa","journal-title":"Clin Infect Dis"},{"key":"12","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.","volume":"39","author":"Pedraza","year":"2020","journal-title":"Lancet"},{"key":"13","doi-asserted-by":"publisher","first-page":"taaa069","DOI":"10.1093\/jtm\/taaa069","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infection.","volume":"2","author":"Shalev","year":"2020","journal-title":"J Travel Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.","volume":"38","author":"Kunichoff","year":"2020","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.","volume":"7","author":"He","year":"2020","journal-title":"Hypertension"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.09.20059964","article-title":"Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years.","volume":"202","author":"Crothers","year":"2020","journal-title":"medRxiv"},{"key":"17","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).","volume":"5","author":"Jehi","year":"2020","journal-title":"JAMA Cardiol"},{"key":"18","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.","volume":"38","author":"Corrao","year":"2020","journal-title":"N Engl J Med"},{"key":"19","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1473-3099(20)30371-6","article-title":"Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study.","volume":"2","author":"Lopez Bernal","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.21037\/atm.2020.03.229","article-title":"The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension.","volume":"8","author":"Ge","year":"2020","journal-title":"Ann Transl Med"},{"key":"21","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1093\/cid\/ciaa624","article-title":"Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study.","volume":"7","author":"Kim","year":"2020","journal-title":"Clin Infect Dis"},{"key":"22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.","volume":"5","author":"Deng","year":"2020","journal-title":"JAMA Cardiol"},{"key":"23","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.","volume":"12","author":"Cheng","year":"2020","journal-title":"Circ Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.","volume":"32","author":"Diefenbach","year":"2020","journal-title":"JAMA"},{"key":"25","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/ejhf.1924","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.","volume":"2","author":"Dobson","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"26","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1053\/j.gastro.2020.05.034","article-title":"Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19.","volume":"15","author":"Mao","year":"2020","journal-title":"Gastroenterology"},{"key":"27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/nm.4004","article-title":"Translational strategies in aging and age-related disease.","volume":"2","author":"Villeda","year":"2015","journal-title":"Nat Med"},{"key":"28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1042\/CS20130407","article-title":"Immune mechanisms in hypertension and vascular injury.","volume":"12","author":"Schiffrin","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2010.12.008","article-title":"NF-\u03baB, inflammation, and metabolic disease.","volume":"1","author":"Ghosh","year":"2011","journal-title":"Cell Metab"},{"key":"30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41577-019-0160-5","article-title":"Immune mechanisms of hypertension.","volume":"1","author":"Sobey","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"31","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev.pathol.4.110807.092145","article-title":"The pathology of chronic obstructive pulmonary disease.","volume":"4","author":"Timens","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40256-013-0058-8","article-title":"Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.","volume":"1","author":"D\u00e9zsi","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"key":"33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.phrs.2016.03.018","article-title":"ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis.","volume":"10","author":"Teixeira","year":"2016","journal-title":"Pharmacol Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","article-title":"Renin-angiotensin system and cardiovascular risk.","volume":"36","author":"Schmidt","year":"2007","journal-title":"Lancet"},{"key":"35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","article-title":"Angiotensin-converting enzyme 2 in lung diseases.","volume":"6","author":"Penninger","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure.","volume":"43","author":"Hui","year":"2005","journal-title":"Nature"},{"key":"37","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","article-title":"Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.","volume":"8","author":"Jenkins","year":"2020","journal-title":"Lancet Respir Med"},{"key":"38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1055\/a-1155-0501","article-title":"The ACE-2 in COVID-19: foe or Friend?","volume":"5","author":"Boehm","year":"2020","journal-title":"Horm Metab Res"},{"key":"39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jacc.2020.05.040","article-title":"Ramipril in High-Risk Patients With COVID-19.","volume":"7","author":"Catal\u00e1","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ahj.2020.05.002","article-title":"Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.","volume":"22","author":"Granger","year":"2020","journal-title":"Am Heart J"},{"key":"41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ahj.2020.05.010","article-title":"Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease.","volume":"22","author":"Rooijakkers","year":"2020","journal-title":"Am Heart J"},{"key":"42","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1111\/jch.14011","article-title":"Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.","volume":"2","author":"Bernales-Salas","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"43","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"6","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"44","volume-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses.","author":"O\u2019connell","year":"2009"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T16:56:16Z","timestamp":1620320176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4,30]]}},"alternative-id":["202902","33886504"],"URL":"https:\/\/doi.org\/10.18632\/aging.202902","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]}}}